![Inez de Greef-van der Sand](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Inez de Greef-van der Sand
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
DegenRx BV
![]() DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Vorstandsvorsitzender | 01.09.2020 | - |
Karriereverlauf von Inez de Greef-van der Sand
Statistik
International
Niederlande | 2 |
Operativ
Chief Executive Officer | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
DegenRx BV
![]() DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Health Technology |